Research Analysts Issue Forecasts for NRXP Q3 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – HC Wainwright issued their Q3 2025 earnings estimates for NRx Pharmaceuticals in a research note issued to investors on Monday, September 8th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.11 EPS, FY2027 earnings at $2.53 EPS, FY2028 earnings at $5.00 EPS and FY2029 earnings at $5.49 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67).

A number of other equities research analysts also recently commented on the stock. D. Boral Capital reiterated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Finally, BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat.com, NRx Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXP opened at $2.97 on Wednesday. The company has a market cap of $58.84 million, a PE ratio of -1.33 and a beta of 1.63. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $6.01. The company has a 50-day simple moving average of $2.81 and a 200-day simple moving average of $2.55.

Institutional Investors Weigh In On NRx Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $56,000. Millennium Management LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $61,000. Anson Funds Management LP lifted its position in shares of NRx Pharmaceuticals by 535.1% during the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after purchasing an additional 993,401 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares in the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.